USA – Becton, Dickinson, and Company (BD), a leading US-based medical device company, has introduced high-throughput, robotics-compatible reagent kits for large-scale single-cell genetic discovery studies.
These kits aim to improve consistency and efficiency in the analysis of genetic material, marking a significant step in genomic research automation.
In collaboration with Hamilton, BD has created an automated solution that replaces traditionally manual processes, accelerating the preparation of materials for genetic sequencing.
This system includes the newly released BD OMICS-One XT WTA Assay and the Hamilton Microlab NGS STAR automated liquid handling platform, which is already widely used in research labs worldwide.
The combination allows researchers to seamlessly integrate BD’s automated reagent kits into existing workflows.
Automating DNA library preparation to streamline genomic workflows
The automation of DNA library preparation is a key advancement for single-cell studies.
Historically, the process has been labor-intensive, involving numerous manual steps that result in data variability and longer turnaround times.
By automating this critical step, BD and Hamilton aim to increase throughput, reduce errors, and enhance data quality, which is vital for reproducible scientific research.
“By automating the complex library preparation process, researchers can scale their sample throughput and expect more consistent results, minimizing the variability introduced by manual procedures,” said Steve Conly, President of BD Biosciences.
“This standardization is crucial for the reproducibility of experiments, which is a cornerstone of scientific research.”
The new solution is designed to benefit genomics applications across fields such as oncology and immunology, where precision and efficiency are critical.
BD’s strategic partnerships and ongoing developments
In addition to launching these innovative reagent kits, BD has also resolved most of its hernia litigation cases, including those in Rhode Island and Ohio.
The company’s financial outlook remains strong, with robust third-quarter results and an 18% year-over-year increase in earnings per share (EPS).
“Hamilton’s advanced automated solutions streamline scientific workflows, maximizing the potential of single-cell multi-omics research,” said Matt Hamilton, CEO of Hamilton.
“Our partnership with BD furthers our mission to provide innovative technologies that accelerate groundbreaking discoveries in science and medicine.”
BD’s continued expansion in medical technologies
BD’s acquisition of Edwards Lifesciences’ Critical Care product group—now rebranded as BD Advanced Patient Monitoring—enhances its portfolio of smart connected care solutions.
This expansion, along with ongoing innovations in automation technology, positions BD as a key player in the healthcare equipment and supplies industry, further supporting its financial growth and commitment to shareholder value.
BD’s strategic focus on expanding its technology offerings aligns with its long-term goals, including increasing its global revenue and reinforcing its position as a leader in the medical device industry.
